Topic Collection Search
Allergy and immunology
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Geriatric medicine / aging
Haematology / blood transfusion
History of medicine
Legal and forensic medicine
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Organisation of health care
Otolaryngology / head and neck surgery
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Quality of care
Statistics and research methods
Swiss newborn screening for severe T and B cell deficiency with a combined TREC/KREC assay – management recommendations
The recent introduction of newborn screening for severe primary T and B cell deficiencies in Switzerland allows rapid identification of patients with severe combined immunodeficiency (SCID). The authors outline the screening procedure currently performed in Switzerland and give recommendations for diagnostic evaluations and precautionary measures against infection in children with abnormal screening test results.
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice
Atezolizumab is an approved therapy for urothelial carcinoma based on results from phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations.
Cancer cells are dependent on a few driver genes for the constitutive activation of the signalling pathways which aid cellular proliferation. Targeting oncogenic-dependent genes has met with success, as demonstrated in several cancer types.
Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry
In recent years, several treatment modalities have proved to be effective in the treatment of neuroendocrine tumours. However, there is currently no consensus on the sequence in which these options are best used.
Recent advancements in sequencing technology, including low-volume and single-cell sequencing, have led us to gain some fascinating new insights that may require us to reflect and adjust our understanding of cancer biology.
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
Pembrolizumab programmed death-1 (PD-1) inhibitor is indicated for treatment of patients with previously untreated metastatic NSCLC with a PD-L1 tumour proportion score (TPS) ≥50%. Its cost effectiveness for this indication has not previously been evaluated in Switzerland.
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study
Recurrent glioblastoma (GBM) is a disease with poor prognosis for which there is no established standard therapy. A recent survey among Swiss neuro-oncology centres has shown considerable differences in treatment recommendations.
The programmed death-1 (PD-1) pathway serves as a checkpoint to limit T-cell mediated immune responses. Blocking the PD-1 receptor on T cells with monoclonal antibodies results in T-cell activation and proliferation and can induce a potent immunotherapeutic antitumour effect.
The HER2 oncogene is overexpressed in different tumour types and drugs specifically targeting it have been successfully used in cancer therapy. Resistance to these drugs ultimately occurs. In this context autophagy was reported to be upregulated.
The Wnt pathway is not only involved in tumourigenesis and cell proliferation, but also contributes to chemoresistance and cancer stem cell propagation, responsible for tumour recurrence after therapy, metastasis and poor patient survival.